

**CAPLIN POINT LABORATORIES LIMITED**

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

		UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2013						UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2013					
Part I Particulars	Unaudited			Unaudited		Audited	Unaudited			Unaudited		Audited	
	Three months ended			Nine months ended		Year ended	Three months ended			Nine months ended		Year ended	
	Mar 31, 2013	Dec 31, 2012	Mar 31, 2012	Mar 31,		June 30, 2012	Mar 31, 2013	Dec 31, 2012	Mar 31, 2012	Mar 31,		June 30, 2012	
	Rs. In Lacs	Rs. In Lacs	Rs. In Lacs	2013	2012	2012	Rs. In Lacs	Rs. In Lacs	Rs. In Lacs	2013	2012	2012	
<b>1</b>	<b>Income</b>												
	a. Net Sales/ income from operations (Net of Excise Duty)	2,796.77	2,963.17	2,597.24	8,426.04	7,304.27	10,529.93	2,886.71	3,189.14	2,600.13	8,790.37	7,424.75	10,706.86
	b. Foreign Exchange Fluctuation	10.91	(107.55)	65.15	181.28	(86.34)	-	10.56	(128.44)	49.12	176.87	(78.78)	-
	c. Share of profits in LLP	103.70	77.61	26.21	248.01	143.78	232.13	-	-	-	-	-	-
	d. Total	<b>2,911.38</b>	<b>2,933.23</b>	<b>2,688.60</b>	<b>8,855.33</b>	<b>7,361.71</b>	<b>10,762.06</b>	<b>2,897.27</b>	<b>3,060.70</b>	<b>2,649.25</b>	<b>8,967.24</b>	<b>7,345.97</b>	<b>10,706.86</b>
<b>2</b>	<b>Expenditure</b>												
	a. Cost of materials consumed	717.95	816.49	965.91	2,269.64	2,339.38	3,113.07	843.02	927.58	1,064.50	2,584.70	2,703.14	3,580.10
	b. Purchase of Stock-in-Trade	1,214.09	1,317.48	1,046.53	3,723.23	3,320.07	4,762.90	1,117.58	1,279.26	894.82	3,477.37	2,822.12	4,141.17
	c. Change in inventories of Finished Goods, work in progress and stock in trade	35.54	(119.35)	14.82	(87.93)	(6.36)	38.57	(34.05)	(120.28)	15.41	(157.67)	(25.09)	15.47
	d. Employees benefit expenses	197.80	174.85	167.48	561.74	441.25	614.14	203.75	181.89	171.74	581.62	454.09	634.82
	e. Depreciation	34.77	33.99	29.37	100.14	84.67	114.43	36.96	36.10	31.38	106.51	90.60	122.59
	f. Amortisation of Intangible Assets	0.27	0.27	-	0.81	-	1.07	0.27	0.27	-	0.81	-	1.07
	g. Foreign Exchange Fluctuation Loss	-	-	-	-	-	481.72	-	-	-	-	-	495.52
	h. Other Expenditure	207.32	198.97	166.22	605.19	537.75	703.75	234.76	225.21	166.46	685.90	596.78	774.92
	i. Total	<b>2,407.74</b>	<b>2,422.70</b>	<b>2,390.33</b>	<b>7,172.82</b>	<b>6,716.76</b>	<b>9,829.65</b>	<b>2,402.29</b>	<b>2,530.03</b>	<b>2,344.31</b>	<b>7,279.24</b>	<b>6,641.64</b>	<b>9,765.66</b>
<b>3</b>	<b>Profit(+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)</b>	<b>503.64</b>	<b>510.53</b>	<b>298.27</b>	<b>1,682.51</b>	<b>644.95</b>	<b>932.41</b>	<b>494.98</b>	<b>530.67</b>	<b>304.94</b>	<b>1,688.00</b>	<b>704.33</b>	<b>941.20</b>
<b>4</b>	<b>Other Income</b>	<b>20.65</b>	<b>47.40</b>	<b>57.24</b>	<b>142.98</b>	<b>185.64</b>	<b>238.95</b>	<b>29.91</b>	<b>55.63</b>	<b>57.40</b>	<b>171.54</b>	<b>185.92</b>	<b>265.48</b>
<b>5</b>	<b>Profit(+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>524.29</b>	<b>557.93</b>	<b>355.51</b>	<b>1,825.49</b>	<b>830.59</b>	<b>1,171.36</b>	<b>524.89</b>	<b>586.30</b>	<b>362.34</b>	<b>1,859.54</b>	<b>890.25</b>	<b>1,206.68</b>
<b>6</b>	<b>Finance cost</b>	<b>(2.54)</b>	<b>(1.86)</b>	<b>(17.57)</b>	<b>(14.91)</b>	<b>(65.89)</b>	<b>(87.69)</b>	<b>(2.58)</b>	<b>(1.86)</b>	<b>(17.57)</b>	<b>(14.96)</b>	<b>(65.89)</b>	<b>(89.44)</b>
<b>7</b>	<b>Profit(+)/Loss(-) from Ordinary Activities after finance cost but before exceptional cost (5-6)</b>	<b>521.75</b>	<b>556.07</b>	<b>337.94</b>	<b>1,810.58</b>	<b>764.70</b>	<b>1,083.67</b>	<b>522.31</b>	<b>584.44</b>	<b>344.77</b>	<b>1,844.58</b>	<b>824.36</b>	<b>1,117.24</b>
<b>8</b>	<b>Exceptional items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9</b>	<b>Profit(+)/Loss(-) from Ordinary Activities before Tax (7-8)</b>	<b>521.75</b>	<b>556.07</b>	<b>337.94</b>	<b>1,810.58</b>	<b>764.70</b>	<b>1,083.67</b>	<b>522.31</b>	<b>584.44</b>	<b>344.77</b>	<b>1,844.58</b>	<b>824.36</b>	<b>1,117.24</b>
<b>10</b>	<b>Provision for Taxation</b>	<b>(115.00)</b>	<b>(125.00)</b>	<b>(30.18)</b>	<b>(400.00)</b>	<b>(117.68)</b>	<b>(190.19)</b>	<b>(142.50)</b>	<b>(147.00)</b>	<b>(36.75)</b>	<b>(459.50)</b>	<b>(150.49)</b>	<b>(239.28)</b>
	Provision for Taxation - earlier years	-	-	(22.13)	-	(22.13)	-	-	-	(22.13)	-	(22.13)	-
	Deferred Tax Provision	(40.08)	(72.86)	(77.50)	(138.75)	(89.86)	(93.76)	(40.08)	(72.86)	(77.50)	(138.75)	(89.86)	(93.76)
	Mat Credit Entitlement	-	-	-	-	-	18.79	-	-	-	-	-	18.79
<b>11</b>	<b>Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)</b>	<b>366.67</b>	<b>358.21</b>	<b>208.13</b>	<b>1,271.83</b>	<b>535.03</b>	<b>818.51</b>	<b>339.73</b>	<b>364.58</b>	<b>208.39</b>	<b>1,246.33</b>	<b>561.88</b>	<b>802.99</b>
<b>12</b>	<b>Extraordinary Item (net of tax expense)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>13</b>	<b>Net Profit(+)/Loss(-) for the period (11-12)</b>	<b>366.67</b>	<b>358.21</b>	<b>208.13</b>	<b>1,271.83</b>	<b>535.03</b>	<b>818.51</b>	<b>339.73</b>	<b>364.58</b>	<b>208.39</b>	<b>1,246.33</b>	<b>561.88</b>	<b>802.99</b>
<b>14</b>	<b>Minority Interest</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(1.05)</b>	<b>(0.81)</b>	<b>(0.26)</b>	<b>(2.51)</b>	<b>(1.45)</b>	<b>(2.34)</b>
<b>15</b>	<b>Net Profit(+)/Loss(-) for the period before minority interest (13-14)</b>	<b>366.67</b>	<b>358.21</b>	<b>208.13</b>	<b>1,271.83</b>	<b>535.03</b>	<b>818.51</b>	<b>338.68</b>	<b>363.77</b>	<b>208.13</b>	<b>1,243.82</b>	<b>560.43</b>	<b>800.65</b>
<b>16</b>	<b>Paid up Equity Share Capital (Face value of the share - Rs 10/- each)</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>	<b>1,511.00</b>
<b>17</b>	<b>Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,516.65</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,473.41</b>
<b>18</b>	<b>Earnings/(Loss) Per Share (EPS) (Not annualised)</b>												
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	2.43	2.37	1.38	8.42	3.54	5.42	2.24	2.41	1.38	8.23	3.71	5.30
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	2.43	2.37	1.38	8.42	3.54	5.42	2.24	2.41	1.38	8.23	3.71	5.30

	Part II	Select information for the Quarter ended 31st March 2013						Select information for the Quarter ended 31st March 2013					
		Unaudited			Unaudited		Audited	Unaudited			Unaudited		Audited
		Three months ended			Nine months ended		Year ended	Three months ended			Nine months ended		Year ended
		Mar 31, 2013	Dec 31, 2012	Mar 31, 2012	Mar 31, 2013		June 30, 2012	Mar 31, 2013	Dec 31, 2012	Mar 31, 2012	Mar 31, 2013		June 30, 2012
<b>A</b>	<b>PARTICULARS OF SHARE HOLDING</b>												
19	Public Shareholding												
	- Number of Shares	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647	6,470,647
	- Percentage of Shareholding	42.82%	42.82%	42.82%	42.82%	42.82%	42.82%	42.82%	42.82%	42.82%	42.82%	42.82%	42.82%
20	Promoters and promoter group Shareholding												
	a) Pledged/Encumbered												
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-	-	-	-	-	-	-
	b) Non-encumbered												
	- Number of Shares	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353	8,639,353
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	57.18%	57.18%	57.18%	57.18%	57.18%	57.18%	57.18%	57.18%	57.18%	57.18%	57.18%	57.18%

B	Particulars	3 months ended 31-03-2013			Notes :
	<b>INVESTOR COMPLAINTS</b>				
	Pending at the beginning of the quarter		Nil		1) The Company operates in one segment only.
	Received during the quarter		16		2) The above standalone unaudited financial results were considered and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 9th May 2013
	Disposed of during the quarter		16		3) The statutory auditors have carried out a limited review of the results for the quarter ended 31st March 2013.
	Remaining unresolved at the end of the quarter		Nil		4) The net profit of the current quarter includes share of profit from Argus Salud Pharma LLP in which controlling interest is held by the Company.
					5) Prior year / period figures are regrouped / rearranged wherever necessary.

Place : Chennai  
Dated : 09.05.2013



M.Jayapal  
Managing Director